Course 5: Doing Right By Birth
Course Overview
This course explores the complex interplay between CAPTA laws, mandatory reporting, and perinatal substance use. It delves into the potential negative consequences of incarceration, overuse of drug testing, and family separation. The video highlights the limitations of urine toxicology testing and the importance of addressing racial inequities in the system. Viewers will learn about the reasons healthcare providers may report patients out of fear and the lack of evidence supporting the effectiveness of removing children from substance-exposed environments. The video advocates for a more compassionate and supportive approach, emphasizing the need for therapeutic alliances, trust, and clinical empathy. Clinicians will gain a deeper understanding of the challenges faced by perinatal individuals with substance use disorders and the importance of advocating for policy changes to improve outcomes.
Course Objectives
Analyze the impact of CAPTA laws and mandatory reporting on perinatal individuals with substance use disorders.
Discuss the implications of incarcerating perinatal individuals for substance use, including the potential negative consequences for both the birthing parent and child.
Evaluate the effectiveness of screening and reporting to state agencies for perinatal substance use, considering the potential for overuse and misuse of drug testing.
Understand the limitations of urine toxicology testing and the implications of false positive results on families, including the potential for injustice and racial inequities.
Explore the reasons why healthcare providers may report patients out of fear, despite the lack of evidence that removing children from substance exposure protects them from fatality due to maltreatment.
Recognize the importance of addressing discrimination as a patient safety issue and the need to decriminalize healthcare.
Advocate for changes in hospital drug testing policies and procedures to reduce the potential for harm and improve patient outcomes.
Support efforts to change state laws related to mandatory reporting and perinatal substance use to prioritize the well-being of families and reduce unnecessary interventions.
Provide support to parents instead of focusing solely on removing children, recognizing the importance of a therapeutic alliance and trust in healthcare.
Practice clinical empathy and prioritize the needs of perinatal individuals with substance use disorders, advocating for a more compassionate and supportive approach to care.
Advocate for a "do right at birth" approach, emphasizing the importance of providing comprehensive care and support to both the mother and child, rather than relying solely on punitive measures.
Target Audience
Clinicians and Staff of Birthing Hospitals
Credit Information
Credit Type
* AMA PRA Category 1™
Number of Credits
0.75
* AMA PRA Category 1 ™ credits are used by physicians and other groups like PAs and certain nurses. Category 1 credits are accepted by the ARDMS, CCI, ACCME, and Sonography Canada.
Faculty
Mishka Terplan, MD, MPH, FACOG, DFASAM: Dr. Mishka Terplan is board certified in both obstetrics and gynecology and in addiction medicine. His primary clinical, research, public health, and advocacy interests lie along the intersections of reproductive and behavioral health. He is based in the Mid-Atlantic where he serves as Medical Director for Friends Research Institute (FRI).
Dr. Terplan has published extensively on health inequities, discrimination, and access to treatment and is internationally recognized as an expert in the care of pregnant and parenting people with substance use disorder. He has been central to guidance document development at the American Congress of Obstetrician Gynecologists (ACOG), the American Society of Addiction Medicine (ASAM) and the Substance Abuse and Mental Health Services Administration (SAMHSA) and has participated in expert panels at Center for Disease Control, Office of the National Drug Control Policy, Office of Women’s Health, US Food and Drug Administration, the National Institutes of Health, and the United Nations Office on Drugs and Crime primarily on issues related to gender, reproduction, and addiction.
In addition to his work for FRI, he is adjunct faculty at the University of California, San Francisco where he is a Substance Use Warmline clinician for the National Clinician Consultation Center.
Disclosure
Mishka Terplan, MD, MPH, FACOG, DFASAM discloses no such relationships exist
In compliance with the Essentials and Standards of the ACCME, the author of this CME tutorial is required to disclose any significant financial or other relationships they may have with commercial interests.
Estimated Time for Completion
0.75 hour
Date of Release
September 11th, 2024
Date of Most Recent Review
April 3rd, 2025
Expiration Date
April 3rd, 2028
Accreditation
Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Iowa Healthcare Collaborative (IHC) and Stader Opioid Consultants (SOC). The Iowa Healthcare Collaborative (IHC) is accredited by the IMS to provide continuing medical education for physicians. Designation: IHC designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the activity. Commercial Support: This activity was developed without support from any ineligible company. *The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company. Disclosure: IHC adheres to the Standards for Integrity and Independence in Accredited Continuing Education. The content of this activity is not related to products or the business lines of an ACCME-defined ineligible company. None of the planners or moderators for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing products used by or on patients. Note: We often receive questions about whether AMA PRA Category 1 Credits™ are accepted for nursing license renewal purposes. Please be informed that most state licensing boards across various disciplines nationwide recognize these credits as valid for continuing education. Many societies and credentialing bodies accept the AMA PRA Category 1 Credit™ as the top-tier continuing education credit and as an equivalent, provided the topic is relevant to the applicant’s field or discipline. After participating in our event, you will receive a Certificate of Attendance detailing the number of AMA PRA Category 1 Credits™ you can claim. This certificate does not automatically award continuing education credit, it is provided for self-reporting requirements and must be submitted to your respective state board for license renewal. We strongly recommend that each participant verify with their specific discipline’s licensing board to ensure acceptance of these credits. Thank you for your attention to this matter, and please feel free to reach out if you have further questions.
0.75 AMA PRA Category 1 Credit™
